Abstract: An apparatus (1) for treating a cancerous target site is provided. The apparatus comprises an electromagnetic emitter (10) comprising one or more electrodes with an electrically insulating coating for preventing electrical contact between the electrodes and the target site. The electromagnetic emitter (10) is configured to provide a tumour treating field at a target site (30) via the one or more electrodes, the tumour treating field being non-ionizing alternating electromagnetic field having a frequency of between 10 kHz to 300 kHz; and further having a magnetic flux density of between 0.1 pT and 1 mT. The apparatus further comprises a heat source (20) configured to provide heating at the target site to cause hyperthermia at the target site. The apparatus is configured to apply the non-ionizing alternating electromagnetic field and the heating independently. The apparatus comprises an electronic controller for electronically controlling the electromagnetic emitter and the heat source.

Abstract: Provided herein are methods and compositions related to treating motor neuron diseases, such as ALS, in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside, pterostilbene and a phosphodiesterase (PDE) inhibitor, including a PDE4 inhibitor such as ibudilast, and also including a thiol/cysteine donor, such as acetylcysteine.

Abstract: The invention relates to the combined use of pterostilbene and quercetin for the production of cancer treatment medicaments. The in vitro growth of melanoma cells B16-F10 (B16M-F10) is inhibited (56%) by combined exposures of short duration (60 min/day) to PTER (40 ?M)+QUER(20 ?M) (˜average values of plasma concentrations measured within the first hour following the IV administration of 20 mg of each polyphenol/kg ˜). The combined intravenous administration of PTER+QUER (20 mg/kg× day) to mice inhibits (73%) the metastatic growth of melanoma B16M-F10 in the liver, a common site for metastasis development. The invention demonstrates that the combination of PTER+QUER inhibits the growth of malignant melanoma metastasis and prolongs the survival of the carrier host.

Abstract: The invention relates to the combined use of pterostilbene and quercetin for the production of cancer treatment medicaments. The in vitro growth of melanoma cells B16-F10 (B16M-F10) is inhibited (56%) by combined exposures of short duration (60 min/day) to PTER (40 ?M)+QUER (20 ?M) (˜average values of plasma concentrations measured within the first hour following the IV administration of 20 mg of each polyphenol/kg ˜). The combined intravenous administration of PTER+QUER (20 mg/kg×day) to mice inhibits (73%) the metastatic growth of melanoma B16M-F10 in the liver, a common site for metastasis development. The invention demonstrates that the combination of PTER+QUER inhibits the growth of malignant melanoma metastasis and prolongs the survival of the carrier host.